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Venous thromboembolism (VTE) such as deep-vein thrombosis (DVT) and pulmonary thromboembolism (PTE) often occurs after
surgery and rarely occurs even before surgery in patients with ovarian cancer. It is well known that levels of plasma D-dimer (DD)
before treatment in most ovarian cancer patients are increased. This study therefore examined whether increased levels of DD are
associated with presence of VTE before treatment of ovarian cancer. Between November 2004 and March 2007, DD levels prior to
initial treatment were measured in 72 consecutive patients with presumed epithelial ovarian cancer (final diagnosis: epithelial ovarian
cancer, n¼60; and epithelial ovarian borderline malignancy, n¼12). Venous ultrasound imaging (VUI) of the lower extremity was
conducted for all patients except for two patients in whom DVT was detected by pelvic computed tomography (CT). When DVT
was found, pulmonary scintigraphy was subsequently performed to ascertain presence of PTE. D-dimer levels were above the cut-off
value (0.5mgml
 1) in 65 of 72 patients (90.2%). Venous ultrasound imaging or CT revealed DVT in 18 of 72 patients (25.0%) and
pulmonary scintigraphy found PTE in 8 patients (11.1%). All patients with VTE were asymptomatic when VTE was found. D-dimer
levels were associated with incidence of VTE (0–1.4mgml
 1; 0 of 26 (0%), 1.5–7.4mgml
 1; 9 of 30 (30%) and X7.5mgml
 1; 9 of 16
(56.3%), P for trend¼0.0003). However, even if 1.5mgml
 1 was used as a cut-off value, this had low specificity and positive
predictive value (47.2, 38.3%), though it had high sensitivity and negative predictive value (100, 100%). Therefore, ovarian cancer
patients with DD level X1.5mgml
 1 should be examined using VUI to detect silent DVT. Patients with VTE underwent preventive
managements including anticoagulant therapy before initial treatment, chemotherapy or surgery, and after surgery. There was no
clinical onset of postoperative VTE in all 72 patients. Measurement of DD levels and subsequent ultrasonography revealed that silent
or subclinical VTE frequently occurs before surgery in ovarian cancer. The usefulness of preoperative assessment of VTE needs
further confirmation in randomised controlled trials.
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Deep-vein thrombosis (DVT) and subsequent pulmonary thrombo-
embolism (PTE) represent potentially lethal perioperative
complications associated with surgery for ovarian cancer (von
Tempelhoff et al, 1998). Deep-vein thrombosis is known to occur
in the postoperative period or during the course of postoperative
chemotherapy in 13.6–27.0% of ovarian cancer patients (Clarke-
Pearson et al, 1983; von Tempelhoff et al, 1998). Several guidelines
(Greets et al, 2001; Nicolaides et al, 2001) have focused on intra-
and postoperative managements for prevention of venous
thromboembolism (VTE). However, large tumours or massive
ascites in ovarian cancer may compress the intrapelvic veins and
increase the risk of DVT even before surgery. For prevention of
DVT after surgery, we usually use elastic stockings during surgery
and intermittent pneumatic compression (IPC) during and after
surgery. However, if DVT exists before treatment of ovarian
cancer, such preventative measures may be ineffective or possibly
dangerous for lethal PTE.
D-dimer (DD) is a degradation product of fibrin and reflects
fibrin concentration. Several studies have reported that levels of
plasma DD before treatment in most ovarian cancer patients are
increased and related to advanced disease, suggesting DD as a
useful tumour marker or prognostic factor of ovarian cancer
(Mirshahi et al, 1992; Gadducci et al, 1996). Although high levels of
DD are generally thought to be associated with the presence of
DVT (Bounameaux et al, 1991; Harrison et al, 1993; Wells et al,
2003; Righini et al, 2006), one study reported that preoperatively
increased DD levels in ovarian cancer are not significantly
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sassociated with risk of subsequent DVT in the postoperative
period and during first-line chemotherapy (von Tempelhoff et al,
1997). However, patients in that study received either low
molecular weight heparin or unfractionated heparin as periopera-
tive anticoagulant therapy, starting 2h before surgery and
continued until postoperative day 7. That study did not examine
associations between increased DD levels and presence of silent
VTE before surgery.
We undertook the present study to clarify whether increased
levels of DD are associated with presence of silent VTE before
treatment for ovarian cancer and whether pretreatment assessment
of silent VTE can contribute to the prevention of clinical onset of
VTE after surgery for ovarian cancer.
MATERIALS AND METHODS
Patients
The study protocol was approved by the Ethical Committee of the
University of Tsukuba Hospital. Between November 2004 and
March 2007, a total of 72 consecutive patients with presumed
epithelial ovarian cancer were enrolled in this study. All patients
provided written informed consent. Initial treatment was per-
formed in the Department of Obstetrics and Gynecology at the
University of Tsukuba Hospital. D-dimer levels were measured on
the first visits to our outpatient clinic 2–5 weeks before initial
treatment of ovarian cancer. Tumour of 60 patients were
histologically confirmed to be ovarian cancer after surgery. The
remaining 12 patients underwent primary surgery and tumours
were histologically diagnosed as ovarian borderline malignancy
(serous type, n¼2; mucinous type, n¼9; endometrioid type,
n¼1). Histology of the ovarian cancers was as follows: serous
adenocarcinoma, n¼31; mucinous adenocarcinoma, n¼6;
endometrioid adenocarcinoma, n¼5; clear cell adenocarcinoma,
n¼14; and undifferentiated carcinoma, n¼4. Criteria of the
International Federation of Gynecology and Obstetrics (FIGO;
1988) were used to classify the 60 patients with ovarian cancer as
stage I (n¼13), stage II (n¼13), stage III (n¼24) or stage IV
(n¼10), while the 12 patients with ovarian borderline malignancy
all had stage I disease. Mean age of patients was 54.5 years (range:
17–87 years). Mean body mass index (BMI) of patients was 23.2
(range: 13.7–35.0). Mean tumour size before treatment was
14.0cm (range: 1.4–43.0cm) according to maximum diameter as
evaluated on magnetic resonance imaging (MRI).
Measurement of plasma DD level
Peripheral blood samples were collected from all patients before
treatment, and DD levels were measured. Blood samples were
drawn from an antecubital vein with atraumatic puncture into
plastic tubes using a two-tube technique, discarding the first
4–5ml. Whole blood was anticoagulated by addition of 9 volumes
to 1 volume of 0.11moll
 1 sodium citrate solution, then
centrifuged at 3000r.p.m. for 10min. Citrate plasma was then
removed and frozen at  201C for up to 3 days before assessment.
D-dimer levels were measured using STA-Liatest D-Di latex
(Diagnostica Stago, Asnie `res, France) sensitised with anti-DD
mouse monoclonal antibody to induce a latex coagulation reaction,
and turbidity was quantified using a spectrophotometer. The
cut-off value of DD level in this method is 0.5mgml
 1.
Detection of DVT
All patients underwent comprehensive imaging of abdominal
extension of the tumour and presence of thrombus in iliac veins
and inferior vena cava using computed tomography (CT) and MRI.
Venous ultrasound imaging (VUI) was performed to detect DVT in
all patients except for two patients who were found to have DVT in
common and external iliac veins on pelvic-enhanced CT. Ultra-
sonography was performed using an ATL HDI5000 system (Philips
Medical Systems, Bothell, WA, USA) equipped with a 3- to
7.5-MHz transducer. Power, pulse repetition frequency and wall
thump filter settings were adjusted for venous vascular studies.
Iliac, femoral, great saphenous, popliteal, peroneal, posttibial and
soleal veins were evaluated bilaterally. Iliac and femoral veins were
assessed in a supine position and other veins were assessed in an
upright position. All veins were imaged on transverse and long-
axis views. Venous lumens were observed while searching for
thrombus by manual compression with transducer and colour
Doppler signals. For evaluation of intrapelvic veins, reactions
during Valsalva manoeuvre were also observed. No reaction
during Valsalva manoeuvre was considered to represent suspected
proximal venous flow disturbance, and we diagnosed intrapelvic
DVT based on the results of enhanced CT.
Pulmonary perfusion scintigraphy
In principle, patients with DVT detected by pelvic CT or VUI were
examined by pulmonary perfusion scintigraphy using Tc-99 to
evaluate the presence of PTE. However, four patients who
displayed old and organised thrombus in popliteal or soleal veins
were omitted from scintigraphy due to the low risk for PTE.
Management of VTE and ovarian cancer
We performed anticoagulant therapy using unfractionated heparin
before initial treatment and after surgery for all patients with VTE.
In addition, one of the following managements was selected in
some patients: placement of inferior vena cava filter (IVCF) before
upfront surgery or neoadjuvant chemotherapy followed by interval
debulking surgery.
Inferior vena cava filter placement was used for preventing
lethal PTE in patients, with DVT in proximal veins such as iliac
and femoral veins or floating DVT in peripheral veins, who
underwent upfront surgery.
Neoadjuvant chemotherapy followed by interval debulking
surgery was selected for patients with apparent stage III/IV
ovarian cancer and chemosensitive tumour histology, that is,
serous or endometrioid type as estimated on CT, excessively
increased CA125 level and cytological findings of ascites. We
administered TC regimen consisting of paclitaxel (175mgm
 2 and
over 3-h infusion) and AUC 6 of carboplatin as neoadjuvant
chemotherapy.
We also used TC regimen as postoperative chemotherapy in
patients with stages Ic–IV ovarian cancer. Patients with ovarian
borderline malignancy did not undergo chemotherapy.
RESULTS
Patient characteristics and risk of VTE
Table 1 shows the relationship between patient characteristics and
risk of VTE (DVT and/or PTE) before treatment. Deep-vein
thrombosis was found in 18 of 72 patients (25.0%) and PTE was
detected in 8 of these 18 patients (DVT alone, n¼10; DVT plus
PTE, n¼8). Though patients with DVT included two patients with
ovarian borderline malignancy, the two patients did not have PTE.
Study variables included age, FIGO stage, histology, BMI, presence
of massive ascites and tumour size. Among these variables, clear
cell histology was significantly associated with both DVT and PTE,
and presence of massive ascites was significantly associated with
DVT. Patients with clear cell histology displayed a higher incidence
of VTE compared to those with nonclear histology (DVT, 50.0 vs
19.0%; PTE, 35.7 vs 5.2%; Table 1). The multivariate analysis for
massive ascites and clear cell histology confirmed that both factors
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swere independently and significantly associated with the risk of
DVT (P¼0.013 and 0.006).
Plasma level of DD
D-dimer levels were above the reference value (0.5mgml
 1)i n6 5o f
out 72 patients with ovarian cancer and borderline malignancy
(90.3%). Figure 1 shows DD levels in patients with and without
VTE (DVT or DVT plus PE). D-dimer levels were significantly
higher in patients with VTE than in patients without VTE (mean
and range of plasma DD levels, 7.95mgml
 1 (1.5–20.0mgml
 1) vs
3.42mgml
 1 (0.2–18.6mgml
 1); P¼0.01). If 1.5mgml
 1 was used
as a cut-off value for DD levels to diagnose VTE, sensitivity,
specificity and positive and negative predictive values were 100,
47.2, 38.3 and 100% (Table 2). D-dimer levels were associated
with incidence of VTE (0–1.4mgml
 1; 0 out of 26 (0%),
1.5–7.4mgml
 1; 9 out of 30 (30%) and X7.5mgml
 1; 9 out of 16
(56.3%), P for trend¼0.0003). Increased DD levels were associated
with higher incidence of VTE (Table 3).
DVT and PE
Deep-vein thrombosis was found in 16 patients with ovarian
cancer and 2 patients with ovarian borderline malignancy.
Pulmonary thromboembolism was confirmed in eight patients
with ovarian cancer. All patients with DVT alone and DVT plus
PTE were asymptomatic when DVT or PTE was found. However,
only one patient with DVT and PTE experienced dyspnoea the day
after pulmonary scintigraphy and was admitted to our hospital on
emergency.
The most proximal location of DVT was the common iliac vein
in one patient, external iliac vein in one patient, femoral vein in
one patient, saphenous vein in one patient, peroneal vein in seven
patients, posttibial vein in one patient and soleal vein in six
patients. For two patients with ovarian borderline malignancy, one
had DVT in the saphenous vein and one had DVT in the soleal
vein.
Management of VTE and cancer treatment
Anticoagulant therapy was performed before initial treatment and
after upfront or interval debulking surgery for all 18 patients with
VTE. In addition, we used placement of IVCF or neoadjuvant
chemotherapy in eight of these patients according to severity of
VTE, stage of ovarian cancer, expected histology of the tumour,
cytological evidence of malignancy and performance status of
patients. As a result, we managed patients with VTE as follows: (1)
anticoagulant therapy alone in 10 patients including 2 patients
with ovarian borderline malignancy; (2) upfront debulking surgery
with placement of IVCF in 4 patients; and (3) neoadjuvant
chemotherapy followed by IDS in 4 patients.
As a result of these mentioned managements, none of these
patients developed clinical manifestations of VTE after surgery.
DISCUSSION
The present study frequently detected silent VTE before treatment
of ovarian cancer and borderline malignancy. Several studies have
documented preoperative DVT and PTE in patients with ovarian
cancer (Goff et al, 1996; Mitsui et al, 2001; Jain et al, 2002). One
study reported that preoperative plasma DD level was high in two
patients who developed PTE postoperatively. High incidence of
silent VTE before surgery seems attributable to the high incidence
of VTE after surgery in ovarian cancer. Our data suggest that
silent or subclinical VTE frequently occurs before surgery, and
progresses and clinically manifests after surgery in ovarian cancer.
Table 1 Incidence of deep-vein thrombosis and pulmonary thromboembolism by patient characteristics with ovarian cancer and borderline tumour
Characteristics DVT OR (95% CI) P-value PTE OR (95% CI) P-value
Age (years)
o50 5/23 (21.7%) Reference 3/23 (13.0%) Reference
X50 13/49 (26.5%) 1.30 (0.40–4.21) 0.66 5/49 (10.2%) 0.76 (0.16–3.49) 0.66
BMI
o25 14/53 (26.4%) Reference 7/53 (13.2%) Reference
X25 4/19 (21.1%) 0.74 (0.21–2.62) 0.64 1/19 (5.3%) 0.36 (0.04–3.18) 0.34
FIGO stage (1989)
Stage I/II 9/38 (23.7%) Reference 5/38 (13.2%) Reference
Stage III/IV 9/34 (26.5%) 1.16 (0.40–3.37) 0.79 3/34 (8.8%) 0.63 (0.14–2.90) 0.56
Histology
Serous carcinoma 5/31 (16.1%) Reference 1/31 (3.2%) Reference
CCC 7/14 (50.0%) 5.20 (1.26–21.5) 0.02 5/14 (35.7%) 16.7 (1.72–161) o0.01
Others 4/15 (26.7%) 1.89 (0.43–8.41) 0.40 2/15 (13.3%) 4.62 (0.38–55.5) 0.51
Borderline tumour 2/12 (16.7%) 1.04 (0.17–6.26) 0.97 0/12 (0.00%) ND
Non-CCC 11/58 (19.0%) Reference 3/58 (5.2%) Reference
CCC 7/14 (50.0%) 4.27 (1.24–14.7) 0.02 5/14 (35.7%) 10.2 (2.07–50.2) o0.01
Massive ascites
a
Absent 10/54 (18.5%) Reference 6/54 (11.1%) Reference
Present 8/18 (44.4%) 3.52 (1.11–11.2) 0.03 2/18 (11.1%) 1.00 (0.18–5.46) 1.00
Tumour size (cm)
o10 6/26 (23.1%) Reference 3/26 (11.5%) Reference
X10 12/46 (26.1%) 1.18 (0.38–3.62) 0.78 5/46 (10.9%) 0.93 (0.20–4.27) 0.93
BMI¼body mass index; CCC¼clear cell carcinoma; CT¼computed tomography; DVT¼deep-vein thrombosis; FIGO¼International Federation of Gynecology and
Obstetrics; ND¼not done; OR¼odds ratio; 95% CI¼95% confidence interval; PTE¼pulmonary thromboembolism.
aMassive ascites was defined as centralisation detected by
CT in this study.
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sAmong six variables considered as risk factors for VTE, clear
cell histology and presence of massive ascites were significantly
associated with VTE before treatment of ovarian cancer. Several
previous reports have postulated that patients with clear cell
adenocarcinoma experience a significantly higher incidence of
VTE (11–42%) compared to those with nonclear carcinoma in the
immediate postoperative period and during primary chemotherapy
(Goff et al, 1996; Recio et al, 1996). In the present study, clear
cell histology was a risk factor for both preoperative silent DVT
and PTE in ovarian cancer patients. Very recently, we used
immunohistochemical methods to reveal that clear cell adeno-
carcinoma shows significantly stronger expression of tissue factor,
a major factor in the procoagulant activities of cancer cells,
compared to nonclear cell adenocarcinoma (Uno et al, 2007).
Massive ascites was also an independent and significant risk factor for
preoperative DVT in ovarian cancer. One explanation is that massive
ascites may increase blood viscosity in blood vessels due to
dehydration. Clear cell histology and massive ascites seem to represent
independent and significant risk factors for silent VTE before
treatment and probably also for VTE after surgery in ovarian cancer.
We revealed that increased levels of DD are associated with
presence of silent VTE before treatment of ovarian cancer. A
suitable cut-off value for detecting VTE in patients with ovarian
cancer seems to be 1.5mgml
 1, as this had a 100% sensitivity and a
100% negative predictive value. However, this cut-off value had
only a 47.2% specificity. Therefore, ovarian cancer patients with
DD level X1.5mgml
 1 should be examined using VUI of the lower
extremity to detect silent DVT.
In the guidelines for preventing VTE following general surgery
reported at the 6th American College of Chest Physicians
Consensus Conference (Greets et al, 2001), patients with malignant
ovarian tumour are classified as the highest risk group. These
guidelines focused on prevention of postoperative VTE and
recommended the use of elastic stockings and IPC during and
after surgery and anticoagulant therapy after surgery in patients
with ovarian cancer. The guidelines included no recommendations
regarding assessment of silent VTE in patients. However, the
present study revealed that patients tend to have VTE such as DVT
and PTE even before treatment of ovarian cancer. There is a
possibility that the management based on preoperative assessment
of VTE may contribute to prevention of clinical manifestation of
VTE after surgery.
In conclusion, measurement of DD level and subsequent
ultrasonography revealed that silent or subclinical VTE frequently
occurs before surgery in ovarian cancer. The usefulness of
preoperative assessment of VTE needs further confirmation in
randomised controlled trials.
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